KEGG   DRUG: Navicixizumab
Entry
D11126                      Drug                                   
Name
Navicixizumab (USAN/INN)
Formula
C6481H9981N1719O2030S54
Exact mass
146098.5544
Mol weight
146189.4051
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMHWVRQA PGQGLEWMGD INPSNGRTSY
KEKFKRRVTL SVDKSSSTAY MELSSLRSED TAVYFCTIHY DDKYYPLMDY WGQGTLVTVS
SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSNFGTQ TYTCNVDHKP SNTKVDKTVE RKCCVECPPC PAPPVAGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT LPPSREKMTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLKS DGSFFLYSKL TVDKSRWQQG
NVFSCSVMHE ALHNHYTQKS LSLSPGK
(heavy chain)
QVQLVQSGAE VKKPGASVKI SCKASGYSFT AYYIHWVKQA PGQGLEWIGY ISNYNRATNY
NQKFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARDY DYDVGMDYWG QGTLVTVSSA
STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL
FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ
VSLTCLVEGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSELTV DKSRWQQGNV
FSCSVMHEAL HNHYTQKSLS LSPGK
(Light chain)
DIVMTQSPDS LAVSLGERAT ISCRASESVD NYGISFMKWF QQKPGQPPKL LIYAASNQGS
GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEVPW TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: H22-H96, H135-L218, H148-H204, H223-h221, H224-h222, H227-h225, H230-h228, H261-H321, H367-H425, h22-h96, h133-L'218, h146-h202, h259-h319, h365-h423, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  Type
Peptide
Efficacy
Antineoplastic
  Type
Monoclonal antibody, bispecific antibody
Comment
Treatment of cancer
Target
DLL4 [HSA:54567] [KO:K06051]
VEGFA [HSA:7422] [KO:K05448]
  Pathway
hsa04014  Ras signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa04330  Notch signaling pathway
hsa04370  VEGF signaling pathway
hsa05200  Pathways in cancer
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Growth factors (RTK-binding)
    VEGFA
     D11126  Navicixizumab (USAN/INN)
 Not elsewhere classified
  Signaling molecules
   Notch signaling
    DLL4
     D11126  Navicixizumab (USAN/INN)
Other DBs
CAS: 1638338-43-8
PubChem: 376219050
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system